Objective To evaluate the predictive value of human epidermal growth factor receptor-2
(HER-2) and P53 in taxanebased and anthracycline-based neoadjuvant chemotherapy …

Background Neoadjuvant chemotherapy provides an excellent model for evaluation of
potential predictive factors. The objective of this study was to evaluate the predictive value of …

Background This study was designed in an attempt to determine the influence of
neoadjuvant chemotherapy on estrogen receptor (ER), progesterone receptor (PR), human …

Purpose The objective of this research was to compare the short-and long-term efficacy of
the following four neoadjuvant chemotherapy (NAC) regimens: docetaxel/carboplatin …

Background Taxane, carboplatin and trastuzumab (TCH) is an effective neoadjuvant
regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer with …

Background: The addition of pertuzumab to trastuzumab in neoadjuvant chemotherapy
(NAC) for antihuman epidermal receptor 2 (HER2) positive breast cancer has shown a …

Background We recently showed HER2-positive breast cancers are less likely to respond to
neoadjuvant anthracycline chemotherapy. Here, we investigated whether HER2-positive …

Objective Determinants of long-term outcome of patients with human epidermal growth
factor receptor 2 (HER2)-positive breast cancer who received neoadjuvant chemotherapy …

Background The incidence of change in HER2 status in primary breast cancer after
neoadjuvant chemotherapy (NAC) and whether the change affect prognosis is not well …

We investigated neoadjuvant chemotherapy for patients with human epidermal growth factor
receptor 2 (HER2)-positive breast cancer. Twenty-eight patients with HER2-positive breast …